ASRS 2024: Clinical characterisation of HK1 associated with retinitis pigmentosa

News
Video

At this year's ASRS meeting, Patrick C. Staropoli, MD, discussed his presentation about autosomal dominant pericentral retinitis pigmentosa

Patrick C. Staropoli, MD, caught up with the Eye Care Network at this year's ASRS meeting. He detailed his presentation on the clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa.

Editor's note: The below transcript has been lightly edited for clarity.

Patrick C. Staropoli, MD: Hi, my name is Patrick Staropoli, an associate physician at Retina Consultants of Texas. I am really excited to be out here in Sweden for ASRS. I just finished my presentation a little while ago. Today, I got to speak about HK1 associated retinitis pigmentosa. It's an autosomal dominant type of retinitis pigmentosa.

What we wanted to do is to sort of characterise all of the clinical features of this disease, because even though it's been researched and described extensively, the papers that are out there in literature really don't have a clear pattern or consensus on what this looks like clinically. So, what we found in our series of patients in our practice is about 30 patients, 60 eyes, 22 unrelated families. And there's a very distinct pattern that you can see on the autofluorescence, where basically it's just the posterior pole, for the most part that is affected. There's a hyperautofluorescent ring that goes around the macula and the arcades. And there's also more of involvement on the nasal side of the periphery rather than the temporal side. So, it's a really distinct pattern. If you pick it up in clinic, your light bulb immediately should go off...this could be HK1-associated retinitis pigmentosa. It's usually inherited in autosomal, dominant fashion. So it does have implications for families.

That was pretty much what we tried to put together today, and make people more aware of it. And one of the other things that's really interesting about this disease process is that the mutation that is most frequent in HK1 actually doesn't affect the functional domain of the protein. So, HK1 is the first step in glycolysis. And even though the protein still functions normally, the question still comes up, "Well, how is this causing damage to the retina?" And as of this point in time, no one really knows for sure. HK1 is known to interact with other proteins that affect apoptosis. And so it's possible that 1 of these peripheral changes is affecting its ability to interact with these other proteins and that leads to unregulated apoptosis, but more research will help us figure that out.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.